ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), achieved an overall response rate (ORR) of 36.4% and disease control rate (DCR) of 100% in checkpoint inhibitor (CPI)-resistant melanoma patients in the ongoing...
Hence then, the article about antengene to present latest clinical results from two studies in cpi resistant solid tumors at asco 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025 )
Also on site :
- Trump says Pam Bondi, a loyalist who oversaw Justice Department upheaval, is out as attorney general
- Misua, Who Was Set to Appear on ‘Drag Race: Philippines’ Season 4, Dies at 27
- Subway Fans Are Buzzing About This BOGO Footlong Deal—Here’s How to Get It